Core Insights - Innovent Biologics reported positive results from the Phase 3 study of mazdutide, a dual agonist targeting GLP-1R and GCGR, showing significant reductions in liver fat content in overweight or obese Chinese adults [1][2][3] Company Overview - Innovent Biologics is a biopharmaceutical company focused on developing high-quality medicines for various diseases, including oncology, autoimmune, cardiovascular, and metabolic disorders [1][9] - The company has launched 10 products and has multiple assets in clinical trials, including five Phase 3 studies for mazdutide [9] Study Details - The GLORY-1 trial involved 610 Chinese adults with a BMI of ≥28 kg/m² or ≥24 kg/m² with at least one weight-related comorbidity, randomized to receive mazdutide or placebo for 48 weeks [2][3] - The study demonstrated that mazdutide treatment led to a mean relative reduction in liver fat content of −63.3% for the 4 mg dose and −73.2% for the 6 mg dose, compared to an 8.2% increase in the placebo group [3][4] Clinical Implications - The results indicate that mazdutide may be more effective than GLP-1 receptor mono-agonists and other dual-target agonists in reducing liver fat, addressing significant unmet clinical needs in metabolic dysfunction-associated fatty liver disease (MAFLD) [2][4] - A high percentage of participants treated with mazdutide achieved significant reductions in liver fat, with 95.5% achieving a ≥30% relative reduction and 77.3% normalizing liver fat levels [4] Market Context - Obesity is a leading risk factor for various chronic diseases, and the prevalence of obesity in China has reached alarming levels, necessitating effective pharmacological interventions [6] - Traditional obesity treatments in China have shown limited efficacy, highlighting the need for innovative solutions like mazdutide [6] Future Prospects - The promising results from the GLORY-1 study support further exploration of mazdutide's clinical value in treating MAFLD and metabolic disorders [5][7] - The first New Drug Application (NDA) for mazdutide was accepted by the CDE of China's NMPA for chronic weight management, indicating potential market entry [8]

浦银国际研究 公司研究 | 医药行业 信达生物（1801.HK）：三项肿瘤管 阳景 浦 线资产公布积极的一期数据 首席医药分析师 银 Jing_yang@spdbi.com 国 (852) 2808 6434 近期公司在 2024 ASCO 和 ESMO Virtual Plenary 会议上公布了 3项肿 际 瘤管线资产积极的一期数据，包括 IBI363 (PD-1/IL-2)积极的一期 PD-1 胡泽宇 CFA 耐药及冷肿瘤数据、IBI343 (CLDN18.2 ADC)潜在同类最佳的一期胰腺癌 医药分析师 疗效安全性数据以及 IBI389 (CLDN18.2/CD3)初步胃癌胰腺癌数据。肿 ryan_hu@spdbi.com 瘤研发管线的持续推进反映了信达强大的研发能力和执行能力。重申 (852) 2808 6446 我们的“买入”评级和目标价 60港元。 2024年6月19日  IBI363 (PD-1/IL-2)一期疗效和安全性数据积极，有望成为实体瘤 公 PD-1 耐药及不响应的潜在疗法：近期公司在 2024 ASCO 和 ESMO 司 Virtual Plenary 会议上公布了潜在 Firs ...

Core Insights - Innovent Biologics, Inc. provided updates on its oncology pipeline, showcasing clinical data on multiple cancer drug candidates at an investor meeting, emphasizing its R&D strategy focused on global innovation [1][2][3] Oncology Pipeline Development Strategy - The company aims to address unmet clinical needs in cancer treatment through an extensive deployment of "IO + ADC" strategies, targeting limitations in current immunotherapies and anti-angiogenic drugs [2][3] - Innovent has developed a product pipeline consisting of 36 new drug candidates, with 22 focused on oncology, leveraging advanced antibody technology and scientific expertise [3] Key Product Milestones - Innovent is advancing its oncology pipeline through clinical proof-of-concept studies and global multi-regional clinical trials, with several promising molecules entering clinical development [4] - IBI363, a first-in-class PD-1/IL-2 α-bias bispecific antibody, has shown promising anti-tumor efficacy across multiple cancer types, including immunotherapy-treated and 'cold' tumors, with over 300 subjects involved in Phase 1 trials [4][5] - IBI343, an innovative TOPO1-inhibitor CLDN18.2 ADC, demonstrated a 40% objective response rate in pancreatic cancer patients, marking it as the first ADC to show breakthrough efficacy in this area [5] - IBI389, a bispecific antibody targeting CLDN18.2/CD3, has shown significant anti-tumor effects in pancreatic cancer, with an objective response rate of 29.6% in clinical trials [6] Future Directions - Innovent plans to continue advancing its oncology product line, focusing on high-quality clinical development and addressing unmet medical needs in cancer treatment [7] - The company emphasizes its unique competitive advantage in next-generation oncology treatment innovations, aiming to empower patients with affordable, high-quality biopharmaceuticals [7][8]

M N 18 Jun 2024 CMB International Global Markets | Equity Research | Company Update Innovent Biologics (1801 HK) Promising PoC results of the potential FIC asset  IBI363 (PD-1/IL-2) demonstrated encouraging signals in IO-failed and cold Target Price HK$55.75 tumors, especially in IO-resistant sq-NSCLC. IBI363 is a potential FIC PD-1/IL-2 (Previous TP HK$55.00) bsAb with a differentiated α-biased IL-2 arm, distinct from other IL-2 mAbs that Up/Downside 46.5% eliminate the receptor α. IBI363 has shown broad- ...

交银国际研究 公司更新 医药 收盘价 目标价 潜在涨幅 2024年6月17日 港元38.05 港元48.00 +26.2% 信达生物 (1801 HK) 早期数据密集公布，下一代肿瘤治疗矩阵雏形初显，重申买入  PD-1/IL-2双抗展现出下一代IO疗法潜质：IBI363（PD-1/IL-2α-bias双抗）治 个股评级 疗实体瘤的I期初步数据显示：在所有实体瘤患者（N=300）和IO经治患 买入 者（N=204）中的ORR分别达到17.3%/17.6%，疗效剂量相关性明显，其 中3mg/kg Q3W剂量组中（N=15）的ORR达到46.7%。IBI363在冷肿瘤/IO 1年股价表现 经治的热肿瘤上取得了明显优于现有IO药物的疗效：1）黑色素瘤中的肢 端和黏膜亚型属于冷肿瘤，在该试验中的 IO 经治患者分别取得 1801 HK 恒生指数 40% 42.9%/18.2%的ORR和71.4%/81.8%的DCR；2）MSS结直肠癌有效疗法较 30% 少，其中肝转移患者（占比70%）对IO疗法更是几乎没有任何响应，而 20% 10% IBI363在0.6-1mg/kg Q2W下取得12.7%的ORR，伴/不伴肝转 ...

Core Insights - Innovent Biologics is set to present multiple clinical study results of mazdutide at the American Diabetes Association's 84th Scientific Sessions, highlighting its significance in obesity treatment [1] - Mazdutide is the first GLP-1R/GCGR dual agonist to succeed in a Phase 3 registration study for overweight and obesity, indicating its potential as a weight management option [1][2] Group 1: Clinical Studies and Presentations - The first Phase 3 study of mazdutide in Chinese adults with obesity and overweight (GLORY-1) will be presented, along with an exploratory analysis on liver steatosis and a Phase 2 study of mazdutide 9 mg [1] - The presentation details include an oral presentation on the efficacy and safety of mazdutide, scheduled for June 23, 2024, and two poster presentations [1] Group 2: Drug Development and Mechanism - Mazdutide (IBI362) is a GLP-1R and GCGR dual agonist developed under an exclusive license agreement with Eli Lilly, showing robust weight loss and glucose-lowering effects in clinical studies [2] - The drug has demonstrated improvements in various cardio-metabolic indicators, including waist circumference, blood lipids, and liver fat content [2] Group 3: Regulatory Progress - The first New Drug Application (NDA) for mazdutide was accepted by the CDE of the NMPA of China for chronic weight management in adults with obesity or overweight in February 2024 [3] Group 4: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biologics for various diseases, with 10 products currently on the market and several in clinical trials [4] - The company collaborates with over 30 global healthcare leaders, including Eli Lilly and Roche, to advance its biopharmaceutical offerings [5]

Core Viewpoint - Innovent Biologics announced that picankibart (IBI112), a recombinant anti-IL-23p19 antibody, successfully met all primary and key secondary endpoints in the Phase 3 CLEAR-1 study for moderate to severe plaque psoriasis, demonstrating significant efficacy and a favorable safety profile [1][2][5]. Group 1: Study Results - CLEAR-1 is the first global Phase 3 registration study in the IL-23p19 class, reporting over 80% of subjects achieving PASI 90 after 16 weeks of treatment [1][2]. - At week 16, 80.3% of subjects receiving picankibart achieved PASI 90 compared to 2.0% for placebo, and 93.5% achieved sPGA 0 or 1 compared to 13.1% for placebo, both with p<0.0001 [2]. - The efficacy of picankibart was maintained through week 52, with 84.9% achieving PASI 90 and 85.9% achieving sPGA 0/1 [3]. Group 2: Secondary Endpoints and Quality of Life - All key secondary endpoints were met, including improvements in PASI 75, PASI 100, sPGA scores, and Dermatology Life Quality Index (DLQI) scores, with results maintained through 52 weeks [4]. - Picankibart showed superiority over placebo in improving all measured parameters, significantly enhancing patients' quality of life [4]. Group 3: Safety Profile - The overall safety profile of picankibart was favorable, with no new safety signals identified compared to previous studies [5]. - Ongoing follow-up of the study will provide complete data for future academic presentations [5]. Group 4: Company and Product Information - Picankibart is a monoclonal antibody developed by Innovent, specifically targeting the IL-23p19 subunit, potentially offering a more effective treatment for psoriasis and other autoimmune diseases [9]. - Innovent is a leading biopharmaceutical company focused on developing high-quality biologics for various diseases, with multiple products in the market and ongoing clinical trials [10].

Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics (1801 HK) Core Insights - Innovent Biologics showcased multiple clinical data at the 2024 ASCO Annual Meeting, highlighting its R&D capabilities with various monoclonal antibodies, bispecific antibodies, and ADCs [3][8] - IBI363 demonstrated promising safety and efficacy in treating cold tumors and IO-resistant tumors, particularly in advanced colorectal cancer patients with a median of ≥3 prior treatment lines [4][9] - IBI389 and IBI343 are positioned well in the market, with IBI389 showing lower treatment-related adverse events compared to standard chemotherapy in pancreatic cancer [4][10] - New data from IBI310 combined with sintilimab indicates significant improvements in pathological complete response rates in MSI-H/dMMR CRC patients [10] Summary by Sections Clinical Data Highlights - In May 2024, Innovent Biologics released clinical data for IBI363, IBI389, IBI343, and IBI310 at ASCO 2024 [3][8] - IBI363 showed good response rates and disease control rates in advanced colorectal cancer, particularly in patients with PD-L1 CPS≥1 [4][9] - IBI389 demonstrated a lower incidence of grade 3 and above treatment-related adverse events compared to standard chemotherapy in advanced pancreatic ductal adenocarcinoma [10] Efficacy and Safety - IBI363 exhibited overall acceptable tolerability and manageable safety, with a lower incidence of grade 3 and above treatment-related adverse events compared to PD-1/PD-L1 therapies [4][9] - IBI343 achieved a notable overall response rate of 40% in a subgroup of pancreatic cancer patients with CLDN18.2 expression ≥60% [5][10] - The combination of IBI310 with sintilimab significantly increased the pathological complete response rate compared to sintilimab monotherapy in CRC patients [10]

2024年5月23日 公司研究 替妥尤单抗注射液上市申请获得受理，商业化前景可期 ——信达生物（1801.HK）公告点评 要点 买入（维持） 当 前价：37.00港元 事件： 公司发布公告，国家药品监督管理局（NMPA）药品审评中心（CDE）已经正式 作者 受理替妥尤单抗注射液（重组抗胰岛素样生长因子1受体抗体（IGF-1R抗体）， 研发代号：IBI311）的新药上市申请（NDA），用于甲状腺眼病（TED）的治疗。 分析师：王明瑞 点评： 执业证书编号：S0930520080004 021-52523867 替妥尤单抗注射液3期注册性临床研究结果积极，详细数据将在学术期刊公布。 wangmingrui@ebscn.com 此次新药申请获得受理是基于一项在中国TED受试者中开展的3期注册临床研 分析师：张瀚予 究RESTORE-1（编号：CTR20223 393）的积极结果。该研究于2024年2月顺 执业证书编号：S0930523070010 利达成主要研究终点，研究显示IBI311组研究眼的眼球突出度、疾病活动程度 021-52523861 zhanghanyu@ebscn.com 和受试者生活质量等方面的改 ...

Financial Performance - Total revenue for 2023 reached RMB 6,206.1 million, a year-on-year increase of 36.2%, with product revenue at RMB 5,728.3 million, up 38.4%[7] - LBITDA decreased significantly by 73.0% year-on-year to RMB 600.1 million, driven by strong product sales growth and improved cost efficiency[7] - The company's cash and short-term financial assets amounted to approximately RMB 10,969.6 million (over USD 1.5 billion), ensuring a strong financial position[7] - Gross margin increased by 2.0 percentage points, while the ratio of sales and marketing expenses to total revenue decreased by 7.3 percentage points[7] - Total revenue for the year ended December 31, 2023, was RMB 6,206.1 million, a 36.2% increase compared to RMB 4,556.4 million in 2022[15] - Product revenue reached RMB 5,728.3 million in 2023, up 38.4% from RMB 4,139.1 million in 2022[15] - Gross profit margin for 2023 was 81.7%, an increase of 2.1 percentage points from 79.6% in 2022[15] - R&D expenses for 2023 were RMB 2,227.6 million, down from RMB 2,871.2 million in 2022[15] - Sales and marketing expenses for 2023 were RMB 3,100.7 million, accounting for 50.0% of total revenue, compared to 56.9% in 2022[15] - Adjusted LBITDA for 2023 was RMB 600.1 million, a 73.0% decrease from RMB 2,221.5 million in 2022[17] - Adjusted net loss for 2023 was RMB 514.5 million, a 79.1% reduction from RMB 2,461.8 million in 2022[17] - Revenue from customer contracts increased to RMB 6,206.1 million in 2023, up from RMB 4,556.4 million in 2022, driven by growth in pharmaceutical product sales, licensing fees, and R&D service income[95] - Pharmaceutical product sales reached RMB 5,728.3 million in 2023, a significant increase from RMB 4,139.1 million in 2022[95] - Licensing fee income rose to RMB 447.4 million in 2023, compared to RMB 417.1 million in 2022, with a notable one-time licensing fee of RMB 5.1 million recorded in 2023[95] - R&D service income surged to RMB 30.3 million in 2023, up from RMB 0.2 million in 2022[95] - Gross profit improved to RMB 5,069.8 million in 2023, up from RMB 3,625.4 million in 2022, reflecting higher revenue and controlled sales costs[94] - R&D expenses decreased to RMB 2,227.6 million in 2023, down from RMB 2,871.2 million in 2022, as the company optimized its R&D investments[99] - Sales and marketing expenses increased to RMB 3,100.7 million in 2023, up from RMB 2,590.8 million in 2022, as the company expanded its market presence[101] - Other income, primarily from interest and government subsidies, rose to RMB 552.4 million in 2023, up from RMB 279.7 million in 2022[97] - The company recorded a tax credit of RMB 116.5 million in 2023, compared to a tax expense of RMB 8.8 million in 2022, due to a refund of withholding tax on licensing fees[103] - Total comprehensive loss for the year improved to RMB 1,013.8 million in 2023, down from RMB 2,200.6 million in 2022, reflecting better operational performance[94] - Adjusted gross profit for 2023 was RMB 5,141,648 thousand, compared to RMB 3,682,300 thousand in 2022[104] - Adjusted R&D expenses for 2023 were RMB 1,974,933 thousand, a decrease from RMB 2,664,708 thousand in 2022[105] - Adjusted administrative and other expenses for 2023 were RMB 543,759 thousand, down from RMB 641,812 thousand in 2022[105] - Adjusted sales and marketing expenses for 2023 were RMB 3,057,482 thousand, up from RMB 2,578,373 thousand in 2022[105] - Adjusted LBITDA for 2023 was RMB 600,148 thousand, an improvement from RMB 2,221,450 thousand in 2022[107] - Adjusted net loss for 2023 was RMB 514,540 thousand, compared to RMB 2,461,834 thousand in 2022[107] - Total assets increased to RMB 20,627,360 thousand in 2023 from RMB 17,588,845 thousand in 2022[109] - Cash and cash equivalents increased to RMB 10,969.6 million in 2023 from RMB 9,166.0 million in 2022[110] - The company has unused long-term bank loan facilities of approximately RMB 2,620.0 million as of December 31, 2023[110] - The company has pledged assets totaling RMB 1,804.9 million for property, plant, and equipment, RMB 275.6 million for land use rights, and RMB 849.8 million for bank deposits as collateral for loans and bank financing[115] - The company's total revenue from the top five customers accounted for 60.8% of the total revenue in 2023, with the largest customer contributing approximately 53.1%[127] - The company's total procurement from the top five suppliers accounted for 53.2% of the total procurement in 2023, with the largest supplier contributing approximately 26.2%[128] - The company's charitable donations for the year ending December 31, 2023, amounted to approximately RMB 154.7 million, compared to RMB 247.2 million in 2022[133] - The company did not issue any bonds during the year ending December 31, 2023[134] - The Board of Directors did not recommend the distribution of a final dividend for the year ending December 31, 2023[135] - The distributable reserve from the share premium account as of December 31, 2023, was RMB 27,324,496,000, compared to RMB 24,705,638,000 in 2022[136] Product Pipeline and R&D - The product pipeline includes 36 high-value candidates, with 10 products already approved for marketing and 3 under NMPA review[3] - Two new innovative products, Fucasso (Igeolonsa Injection) and Xinbile (Tolexizumab Injection), were approved for marketing in China[8] - Tyvyt (Sintilimab Injection) and Byvasda (Bevacizumab Injection) were approved for new indications and included in the NRDL (2023 edition)[8] - The company's product portfolio expanded to 10 commercialized products, with continued addition of new indications and NRDL coverage[8] - R&D efforts focus on oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology, with 18 new drug candidates in clinical trials[3] - Orelabrutinib tablets received approval for a second indication, benefiting more CML patients[9] - The company has 3 products under NMPA review, 5 products in Phase 3 or key clinical studies, and 18 molecules in early clinical research[9] - Fuzerex (KRAS G12C) and Taletrectinib (ROS1) are under NDA priority review, expected to be approved in 2024[9] - Sintilimab (Tyvyt®) achieved a new NSCLC indication and submitted an sNDA for EMC treatment in April 2024[9] - IBI362 (Mazdutide) reached primary and key secondary endpoints in the GLORY-1 study, with NDA submission for weight loss in February 2024[11] - IBI311 (anti-IGF-1R) achieved primary endpoints in the RESTORE-1 Phase 3 trial, with NDA submission planned for TED treatment[11] - The company plans to initiate a Phase 1 trial for Mazdutide in obese adolescents in China in 2024[11] - IBI112 (IL-23p19) demonstrated best-in-class long-term efficacy in a 58-week Phase 2 trial, with Phase 3 registration expected to support NDA submission in 2024[12] - The company’s Suzhou facility has 60,000L antibody production capacity, and the Hangzhou facility has 170,000L capacity (80,000L completed, 90,000L planned)[13] - The company's commercial product portfolio expanded to 10 products, with two new innovative products approved in China[18] - Four NDAs and sNDAs are under review by the NMPA, including IBI344, IBI351, and IBI362[18][19] - IBI362 (Mazdutide), a GLP-1R/GCGR dual agonist, is undergoing five Phase 3 clinical trials in China for overweight or obese adults (GLORY-1 and GLORY-2) and T2D patients (DREAMS-1, DREAMS-2, and DREAMS-3). The company expects to read out Phase 3 results for DREAMS-1 and DREAMS-2 in 2024 to support a second NDA submission for T2D treatment[20] - IBI112 (Piconcibart), a recombinant anti-IL-23p19 antibody, completed the first patient dosing in its Phase 3 trial (CLEAR) for moderate-to-severe plaque psoriasis in February 2023. The company expects to read out Phase 3 results in 2024 to support NDA submission[20] - IBI311, a recombinant anti-IGF-1R monoclonal antibody, achieved the primary endpoint in its Phase 3 trial (RESTORE-1) for TED in February 2024, with NDA submission expected in 2024[20] - IBI302 (Efdamrofusp alfa), an anti-VEGF/complement bispecific fusion protein, showed positive PoC results and completed the first patient dosing in its Phase 3 trial (STAR) for nAMD in October 2023[20] - IBI310, a novel anti-CTLA-4 monoclonal antibody, demonstrated positive PoC results and plans to initiate a Phase 3 trial in 2024 for neoadjuvant treatment of resectable MSI-H/dMMR colon cancer in combination with Sintilimab[20] - IBI363 (PD-1/IL-2) showed encouraging preliminary efficacy and safety in IO-resistant or non-responsive tumors, with preclinical results published in Nature Cancer[21][22] - The company advanced eight innovative molecules to the IND preparation stage in 2023, adding long-term momentum for global innovation and sustainable growth[22] - Strategic collaborations were established, including a partnership with Shengxin Biotech to develop SGB-3908, an siRNA candidate targeting AGT for hypertension treatment[22] - The company has 10 commercialized products, with 3 under NMPA review and 5 in Phase 3 or pivotal clinical studies, along with 18 molecules in early clinical research[31] - Two innovative products, Fucasso (Igeocel Injection) and Xinbile (Tolexizumab Injection), were approved in China in 2023[27] - The company expects to receive approval for two innovative products, Fuzerex (KRAS G12C) and Taletrectinib (ROS1), in 2024 for NSCLC treatment[28] - The company submitted an sNDA for Tyvyt (Sintilimab Injection) combined with Fruquintinib for 2L EMC treatment, which was accepted by NMPA with priority review status in April 2024[31] - The company initiated a Phase 3 trial for IBI310 (CTLA-4) combined with Sintilimab for colon cancer neoadjuvant therapy in March 2024[31] - IBI363 (PD-1/IL-2) and IBI389 (CLDN18.2/CD3) are advancing in early clinical studies, with early clinical data expected to be released at medical conferences in 2024[32] - IBI362 (Mazdutide) achieved primary and key secondary endpoints in the GLORY-1 study, and the company submitted the first NDA for weight loss in February 2024, with plans to submit a second NDA for T2D treatment based on DREAMS-1 and DREAMS-2 results[33] - IBI311, the first domestic anti-IGF-1R monoclonal antibody for TED, reached the primary endpoint in the RESTORE-1 Phase 3 trial in February 2024, with plans to submit an NDA and release full results at medical conferences in 2024[34] - IBI112 (Piconcibai, IL-23p19) is in Phase 3 registration clinical studies for psoriasis, expected to be completed in 2024 to support NDA submission, showing best-in-class long-term efficacy and extended dosing intervals[35] - IBI343 (CLDN18.2 ADC) demonstrated best-in-class potential in MRCT Phase 1b studies for 3L GC, with preparations underway for MRCT Phase 3 trials[36] - The company has 10 products on the market, 3 under NDA review, 5 in Phase 3 or key clinical trials, and 18 molecules in early clinical stages[37] - IBI362 (Mazdutide) is in five Phase 3 clinical trials for obesity and T2D, with GLORY-1 results to be presented at medical conferences in 2024[33] - IBI128, a potential best-in-class XOI, is undergoing overseas Phase 3 clinical studies for hyperuricemia in gout patients, with plans to initiate Phase 1 and 2 trials in China in 2024[34] - The company is advancing a diverse pipeline of innovative drugs in CVM, with plans to enter clinical stages in 2024, aiming to strengthen its strategic position in the field[34] - IBI112 (Piconcibai, IL-23p19) demonstrated superior long-term efficacy and extended dosing intervals in a 58-week Phase 2 trial, supporting its advancement in autoimmune diseases[35] - The company's commercialized product portfolio has expanded to 10 products, including Tyvyt (sintilimab injection), Bevacizumab injection, Suliximab (adalimumab injection), Rituximab injection, Pemigatinib tablets, Olverembatinib tablets, Ramucirumab injection, Selpercatinib, Igeocel injection, and Tolezumab injection[40] - Tyvyt (sintilimab injection) has been approved for seven indications in China, including lung cancer, liver cancer, gastric cancer, esophageal cancer, and classical Hodgkin lymphoma[41] - In May 2023, the NMPA approved the seventh indication for Tyvyt (sintilimab injection) for the treatment of EGFR-mutated non-squamous NSCLC patients who failed EGFR-TKI therapy[42] - In February 2024, Tyvyt (sintilimab injection) was approved for marketing in Macau by the Macau Drug Administration[42] - In April 2024, the company submitted an sNDA for Tyvyt (sintilimab injection) combined with fruquintinib for the treatment of 2L EMC, which was accepted by the NMPA[42] - In January 2023, two new indications for Tyvyt (sintilimab injection) for 1L GC and 1L ESCC were included in the 2022 NRDL, making it the first and only PD-1 inhibitor for GC included in the NRDL[43] - In December 2023, the seventh indication for Tyvyt (sintilimab injection) for EGFR-mutated non-squamous NSCLC patients who failed EGFR-TKI therapy was included in the 2023 NRDL[43] - In June 2023, the NMPA approved the eighth indication for Bevacizumab injection, combined with Tyvyt (sintilimab injection) and chemotherapy for the treatment of EGFR-mutated non-squamous NSCLC patients who failed EGFR-TKI therapy[46] - In January 2023, seven indications for Bevacizumab injection were included in the 2022 NRDL, including three new indications for epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer[47] - In December 2023, the eighth indication for Bevacizumab injection was included in the 2023 NRDL[47] - Dabao Hua (Rituximab Injection) had all approved indications included in the 2022 NRDL, including two new indications for maintenance therapy of previously untreated follicular lymphoma and treatment of chronic lymphocytic leukemia[48] - Sulixin (Adalimumab Injection) was approved for eight indications in China, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease[49] - Sulixin (Adalimumab Injection) had eight indications included in the 2022 NRDL, including two new indications for Crohn's disease and pediatric Crohn's disease[50] - Dabotan (Pemigatinib Tablets) was included in Taiwan's health insurance reimbursement for the treatment of adult patients with locally advanced or metastatic CCA who have received at least one systemic therapy and have confirmed FGFR2 fusion or rearrangement[51] - Olverembatinib Tablets were approved by NMPA for the treatment of CML-CP patients resistant and/or intolerant to first- and second-generation TKIs[53] - Olverembatinib Tablets were included in the 2022 NRDL for the treatment of adult patients with CML-CP and CML-AP with T315I mutation[53] - Cyramza (Ramucirumab) was approved for two indications in mainland China, including second-line treatment for advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma and treatment for hepatocellular carcinoma patients with AFP ≥400 ng/mL who have previously received sorafenib treatment[55] - Retsevmo (Selpercatinib) was conditionally approved in mainland China for the treatment of adult patients with RET gene fusion-positive locally advanced or metastatic NSCLC and adult and pediatric patients 12 years and older with advanced or metastatic MTC